Status:
COMPLETED
High Dose Camptothecin-11 (CPT-11) in Recurrent Unresectable Malignant Glioma
Lead Sponsor:
Kentuckiana Cancer Institute
Conditions:
Malignant Glioma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this study is to compare the response to treatment and side effects associated with high dose irinotecan in patients with recurrent brain tumors.
Detailed Description
This is a phase I/II study of high dose irinotecan in patients with recurrent unresectable malignant glioma on steroids/anti-epileptics. The purpose is to compare the response to treatment and side ef...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- recurrent, unresectable primary CNS neoplasm per MRI
- ECOG status of 2 or less
- no prior therapy with camptothecans
- on an enzyme-inducing antiepileptic
Exclusion
Key Trial Info
Start Date :
August 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2008
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00283556
Start Date
August 1 2001
End Date
December 1 2008
Last Update
January 20 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kentuckiana Cancer Institute
Louisville, Kentucky, United States, 40202